Cancer Institute A national cancer institute
designated cancer center

Ronald Levy, MD

Publication Details

  • Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma BLOOD Ai, W. Z., Tibshirani, R., Taidi, B., Czerwinski, D., Levy, R. 2009; 113 (23): 5743-5746

    Abstract:

    Previous studies demonstrated that vaccination-induced tumor-specific immune response is associated with superior clinical outcome in patients with follicular lymphoma. Here, we investigated whether this positive correlation extends to overall survival (OS). We analyzed 91 untreated patients who received CVP chemotherapy (cyclophosphamide, vincristine, and prednisone) followed by idiotype vaccination. Idiotype proteins were produced either by the hybridoma method or by expression of recombinant idiotype-encoding sequences in mammalian or plant-based expression systems. We found that achieving a complete response/complete response unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independent factors that each correlated with longer OS at 10 years (89% vs 68% with or without a CR/CRu, P = .024; 90% vs 69% with or without tumor-specific antibody production; P = .027). In the subset of patients who received hybridoma-generated vaccines, we found that anti-idiotype production was even more highly associated with superior OS (P < .002); this was the case even in patients with a partial response (PR) to CVP (P < .001).

    View details for DOI 10.1182/blood-2009-01-201988

    View details for Web of Science ID 000266656100013

    View details for PubMedID 19346494

Stanford Medicine Resources:

Footer Links: